Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Carolina Research

Neither a doctor nor a teaching hospital

Research payments

$831,340

182 payments

Through program year 2025, Carolina Research is reported as receiving $831,340 in research payments, across 182 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $70,523 13
2024 Research $96,898 26
2023 Research $127,437 36
2022 Research $19,926 13
2021 Research $76,288 30
2020 Research $64,448 25
2019 Research $375,820 39

Breakdown

Who paid Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $283,003 83 payments
  2. GlaxoSmithKline, LLC. $226,893 19 payments
  3. Teva Pharmaceuticals USA, Inc. $140,154 21 payments
  4. Allergan Inc. $54,035 11 payments
  5. AbbVie, Inc. $49,695 26 payments
  6. Celgene Corporation $39,119 3 payments
  7. Genentech, Inc. $29,547 6 payments
  8. Pfizer Inc. $7,893 12 payments
  9. Mylan Specialty L.P. $1,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet $245,246 63 payments
  2. A Randomised, Double-Blind, Parallel Group, Multicentre, Stratified, S $196,748 9 payments
  3. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $137,416 20 payments
  4. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) $28,817 2 payments
  5. vixarelimab ulcerative colitis study $28,440 5 payments
  6. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $23,114 2 payments
  7. A Randomised Phiii Study to Assess the Effect of 100 MG SC Mepolizumab $21,430 6 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $18,624 5 payments
  9. M16-067 $17,165 6 payments
  10. A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) $11,037 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record